U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination
    • Showing Current items.

    EIF4A1 eukaryotic translation initiation factor 4A1 [ Homo sapiens (human) ]

    Gene ID: 1973, updated on 14-Nov-2024

    GeneRIFs: Gene References Into Functions

    GeneRIFPubMed TitleDate
    Genetic evidence supporting potential causal roles of EIF4 family in breast cancer: a two-sample randomized Mendelian study.

    Genetic evidence supporting potential causal roles of EIF4 family in breast cancer: a two-sample randomized Mendelian study.
    Shi JY, Wen R, Chen JY, Feng YQ, Zhang YY, Hou SJ, Xi YJ, Wang JF, Zhang YF., Free PMC Article

    09/4/2024
    mTORC1/S6K1 signaling promotes sustained oncogenic translation through modulating CRL3[IBTK]-mediated ubiquitination of eIF4A1 in cancer cells.

    mTORC1/S6K1 signaling promotes sustained oncogenic translation through modulating CRL3(IBTK)-mediated ubiquitination of eIF4A1 in cancer cells.
    Jiao D, Sun H, Zhao X, Chen Y, Lv Z, Shi Q, Li Y, Wang C, Gao K., Free PMC Article

    06/27/2024
    eIF4A1-dependent mRNAs employ purine-rich 5'UTR sequences to activate localised eIF4A1-unwinding through eIF4A1-multimerisation to facilitate translation.

    eIF4A1-dependent mRNAs employ purine-rich 5'UTR sequences to activate localised eIF4A1-unwinding through eIF4A1-multimerisation to facilitate translation.
    Schmidt T, Dabrowska A, Waldron JA, Hodge K, Koulouras G, Gabrielsen M, Munro J, Tack DC, Harris G, McGhee E, Scott D, Carlin LM, Huang D, Le Quesne J, Zanivan S, Wilczynska A, Bushell M., Free PMC Article

    03/9/2023
    eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma.

    eIF4A1 Is a Prognostic Marker and Actionable Target in Human Hepatocellular Carcinoma.
    Steinmann SM, Sánchez-Martín A, Tanzer E, Cigliano A, Pes GM, Simile MM, Desaubry L, Marin JJG, Evert M, Calvisi DF., Free PMC Article

    02/15/2023
    eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model.

    eIF4A/PDCD4 Pathway, a Factor for Doxorubicin Chemoresistance in a Triple-Negative Breast Cancer Cell Model.
    González-Ortiz A, Pulido-Capiz A, Castañeda-Sánchez CY, Ibarra-López E, Galindo-Hernández O, Calderón-Fernández MA, López-Cossio LY, Díaz-Molina R, Chimal-Vega B, Serafín-Higuera N, Córdova-Guerrero I, García-González V., Free PMC Article

    01/11/2023
    Epigenetic regulation of EIF4A1 through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling in prostate cancer.

    Epigenetic regulation of EIF4A1 through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling in prostate cancer.
    Wang C, Leavenworth J, Zhang C, Liu Z, Yuan KY, Wang Y, Zhang G, Wang S, Cui X, Zhang Y, Bae S, Zhou J, Wang L, Liu R., Free PMC Article

    05/14/2022
    Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules.

    Targeting eIF4A-Dependent Translation of KRAS Signaling Molecules.
    Singh K, Lin J, Lecomte N, Mohan P, Gokce A, Sanghvi VR, Jiang M, Grbovic-Huezo O, Burčul A, Stark SG, Romesser PB, Chang Q, Melchor JP, Beyer RK, Duggan M, Fukase Y, Yang G, Ouerfelli O, Viale A, de Stanchina E, Stamford AW, Meinke PT, Rätsch G, Leach SD, Ouyang Z, Wendel HG., Free PMC Article

    09/18/2021
    High intratumoral expression of eIF4A1 promotes epithelial-to-mesenchymal transition and predicts unfavorable prognosis in gastric cancer.

    High intratumoral expression of eIF4A1 promotes epithelial-to-mesenchymal transition and predicts unfavorable prognosis in gastric cancer.
    Gao C, Guo X, Xue A, Ruan Y, Wang H, Gao X.

    12/19/2020
    Identification and characterization of hippuristanol-resistant mutants reveals eIF4A1 dependencies within mRNA 5' leader regions.

    Identification and characterization of hippuristanol-resistant mutants reveals eIF4A1 dependencies within mRNA 5' leader regions.
    Steinberger J, Shen L, J Kiniry S, Naineni SK, Cencic R, Amiri M, Aboushawareb SAE, Chu J, Maïga RI, Yachnin BJ, Robert F, Sonenberg N, Baranov PV, Pelletier J., Free PMC Article

    11/21/2020
    The mRNA helicase eIF4A1 is involved in unwinding the G4 in the 5'-UTR of CtlP mRNA through its cooperation with ALC1.

    ALC1/eIF4A1-mediated regulation of CtIP mRNA stability controls DNA end resection.
    Mejías-Navarro F, Rodríguez-Real G, Ramón J, Camarillo R, Huertas P., Free PMC Article

    08/1/2020
    a number of new small molecules have been reported as having the capacity to target and inhibit eIF4A. Here, we undertook a comparative analysis of their biological activity and specificity relative to the eIF4A inhibitor, hippuristanol.

    A comparative study of small molecules targeting eIF4A.
    Naineni SK, Itoua Maïga R, Cencic R, Putnam AA, Amador LA, Rodriguez AD, Jankowsky E, Pelletier J., Free PMC Article

    06/20/2020
    remodels local 5' untranslated region structures

    mRNA structural elements immediately upstream of the start codon dictate dependence upon eIF4A helicase activity.
    Waldron JA, Tack DC, Ritchey LE, Gillen SL, Wilczynska A, Turro E, Bevilacqua PC, Assmann SM, Bushell M, Le Quesne J., Free PMC Article

    03/21/2020
    This work demonstrates the importance of eIF4A in translational control of pancreatic tumour metabolism.

    eIF4A supports an oncogenic translation program in pancreatic ductal adenocarcinoma.
    Chan K, Robert F, Oertlin C, Kapeller-Libermann D, Avizonis D, Gutierrez J, Handly-Santana A, Doubrovin M, Park J, Schoepfer C, Da Silva B, Yao M, Gorton F, Shi J, Thomas CJ, Brown LE, Porco JA Jr, Pollak M, Larsson O, Pelletier J, Chio IIC., Free PMC Article

    02/29/2020
    Elatol's identification as an eIF4A1 inhibitor with in vivo antitumor activities provides proof of principle for target-based screening against this highly promising target for cancer therapy.

    Target-Based Screening against eIF4A1 Reveals the Marine Natural Product Elatol as a Novel Inhibitor of Translation Initiation with In Vivo Antitumor Activity.
    Peters TL, Tillotson J, Yeomans AM, Wilmore S, Lemm E, Jiménez-Romero C, Amador LA, Li L, Amin AD, Pongtornpipat P, Zerio CJ, Ambrose AJ, Paine-Murrieta G, Greninger P, Vega F, Benes CH, Packham G, Rodríguez AD, Chapman E, Schatz JH., Free PMC Article

    11/9/2019
    Results indicate that ubiquitin specific peptidase 9, X-linked (USP9X) is a regulator of the translation initiation process via deubiquitination of eukaryotic translation initiation factor 4A1 (eIF4A1), which is a substrate of USP9X in vivo.

    USP9X controls translation efficiency via deubiquitination of eukaryotic translation initiation factor 4A1.
    Li Z, Cheng Z, Raghothama C, Cui Z, Liu K, Li X, Jiang C, Jiang W, Tan M, Ni X, Pandey A, Liu JO, Dang Y., Free PMC Article

    07/27/2019
    Results suggest that rev protein, HIV-1 (Rev) regulates the association of nuclear cap-binding protein NCBP 80 kDa subunit (CBP80) and eukaryotic translation initiation factor 4A1 (eIF4AI) with the unspliced mRNA in the cytoplasm and the nucleus, respectively, during HIV-1 replication.

    A Rev-CBP80-eIF4AI complex drives Gag synthesis from the HIV-1 unspliced mRNA.
    Toro-Ascuy D, Rojas-Araya B, García-de-Gracia F, Rojas-Fuentes C, Pereira-Montecinos C, Gaete-Argel A, Valiente-Echeverría F, Ohlmann T, Soto-Rifo R., Free PMC Article

    07/6/2019
    Besides catalyzing serine synthesis, PHGDH promotes pancreatic cancer development through enhancing the translation initiations by interacting with eIF4A1 and eIF4E.

    Phosphoglycerate dehydrogenase promotes pancreatic cancer development by interacting with eIF4A1 and eIF4E.
    Ma X, Li B, Liu J, Fu Y, Luo Y., Free PMC Article

    06/29/2019
    RocA targets the "bi-molecular cavity" formed characteristically by eIF4A1 and a sharply bent pair of consecutive purines in the RNA to inhibit genetic translation.

    The Translation Inhibitor Rocaglamide Targets a Bimolecular Cavity between eIF4A and Polypurine RNA.
    Iwasaki S, Iwasaki W, Takahashi M, Sakamoto A, Watanabe C, Shichino Y, Floor SN, Fujiwara K, Mito M, Dodo K, Sodeoka M, Imataka H, Honma T, Fukuzawa K, Ito T, Ingolia NT., Free PMC Article

    06/29/2019
    Star-PAP-specific polyadenylation sites usage regulates the expression of the eukaryotic translation initiation factor EIF4A1, the tumor suppressor gene PTEN and the long non-coding RNA NEAT1.

    Distinct regulation of alternative polyadenylation and gene expression by nuclear poly(A) polymerases.
    Li W, Li W, Laishram RS, Hoque M, Ji Z, Tian B, Anderson RA., Free PMC Article

    10/14/2017
    our data demonstrate that the common effects of eIF4A1 and eIF4E on translation are mediated by the coding region and 3'UTR

    Differential Regulation of the Melanoma Proteome by eIF4A1 and eIF4E.
    Joyce CE, Yanez AG, Mori A, Yoda A, Carroll JS, Novina CD., Free PMC Article

    07/29/2017
    our data identify the eIF4F complex as an important upstream regulator of TORC1, which acts via TSC2 to inactivate TORC1 upon withdrawal of amino acids

    eIF4A inactivates TORC1 in response to amino acid starvation.
    Tsokanos FF, Albert MA, Demetriades C, Spirohn K, Boutros M, Teleman AA., Free PMC Article

    06/10/2017
    Our results demonstrate that miR-133a plays a pivotal role in colorectal cancer by inhibiting cell proliferation, invasion, and migration by targeting oncogenic eukaryotic translation initiation factor 4A1, which acts as a tumor suppressor and may provide a new potential therapeutic target in colorectal cancer

    miR-133a acts as a tumor suppressor in colorectal cancer by targeting eIF4A1.
    Li W, Chen A, Xiong L, Chen T, Tao F, Lu Y, He Q, Zhao L, Ou R, Xu Y.

    06/10/2017
    miR-1284 can function as a new regulator to reduce gastric cancer multidrug resistant cells by targeting EIF4A1.

    MiR-1284 modulates multidrug resistance of gastric cancer cells by targeting EIF4A1.
    Cao W, Wei W, Zhan Z, Xie Y, Xiao Q.

    12/31/2016
    Studies indicate a developing focus on targeting eukaryotic initiation factor 4A eIF4A1 and eIF4A2 as cancer therapy.

    Translational dysregulation in cancer: eIF4A isoforms and sequence determinants of eIF4A dependence.
    Raza F, Waldron JA, Quesne JL.

    09/17/2016
    Immunohistochemical analysis was performed on over 3000 breast tumors to investigate the relationship among expression of eIF4A1, the helicase-modulating proteins eIF4B, eIF4E and PDCD4, and clinical outcome.

    The malignant phenotype in breast cancer is driven by eIF4A1-mediated changes in the translational landscape.
    Modelska A, Turro E, Russell R, Beaton J, Sbarrato T, Spriggs K, Miller J, Gräf S, Provenzano E, Blows F, Pharoah P, Caldas C, Le Quesne J., Free PMC Article

    09/12/2015
    firstprevious page of 3 nextlast